Ginkgo bioworks completes acquisition of zymergen

Boston and emeryville, calif. , oct. 19, 2022 /prnewswire/ -- today, ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming, and zymergen (nasdaq: zy) announced that ginkgo has completed its previously announced acquisition of zymergen.

DNA Ratings Summary

DNA Quant Ranking